Početna › Dijabetes tipa 2 › Missouri
Kliničke studije za Dijabetes tipa 2 u državi Missouri
20 studija za Dijabetes tipa 2 traži sudionike na lokacijama u državi Missouri.
Gradovi u državi Missouri
Službeni tekst studije (engleski)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Jefferson City Medical Group, Jefferson City
- Johnson County ClinTrials, Kansas City
- St. Louis Heart and Vascular, P.C., St Louis
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07064473A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- StudyMetrix Research, LLC, City of Saint Peters
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07754461A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Washington University School of Medicine, St Louis
- Saint Louis Heart and Vascular, St Louis
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 55 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06112418A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Kansas City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07776509A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Clinical Research Professionals, Chesterfield
- Clinvest Headlands Llc, Springfield
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07282600A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Kansas City
- Research Site, Kansas City
- Research Site, St Louis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07784270A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Columbia
- AURORA-2 Clinical Site, St Louis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Kansas City VA Medical Center, Kansas City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351058A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
- Headlands Research, Springfield
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07415954Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
- Elixia MNA, City of Saint Peters
- Clinical Research Consultants, LLC, Kansas City
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07271186A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Jefferson City
- Research Site, Kansas City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT07662213Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Alliance for Multispecialty Research - Kansas City, Kansas City
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684144A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Research Site, Kansas City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07662135AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Johnson County ClinTrials, Kansas City
- Amicis Centers of Clinical Research, St Louis
U tijeku regrutacijaFaza 3
Od 45 godina i više · Oba spola · Ažurirano 1. ruj 2026. · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
- Research Site, Kansas City
- Research Site, St Louis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 31. kol 2026. · NCT07662044Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
- Jefferson City Medical Center, Jefferson City
- Clay Platte Family Medicine, Kansas City
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 17. kol 2026. · NCT07527650Role of KATP Channel Loss in Type 2 Diabetes
- Washington University in St. Louis, St Louis
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 65 godina · Oba spola · Ažurirano 10. kol 2026. · NCT06830096Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
- University of Missouri School of Medicine, Columbia
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 70 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06335771Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
- University of Missouri School of Medicine, Columbia
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 do 70 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06571474Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
- Washington University School of Medicine, St Louis
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 12 do 17 godina · Oba spola · Ažurirano 18. pro 2025. · NCT05277558Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.